Clinical observation of Entecavir combined Liuweiwuling Pian in the treatment of chronic hepatitis B patients with HBeAg+
10.3760/cma.j.issn.1008-6706.2014.14.007
- VernacularTitle:恩替卡韦联合六味五灵片治疗乙型肝炎病毒e 抗原阳性慢性乙型肝炎的临床观察
- Author:
Lixia BI
;
Xinzhi LIU
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Hepatitis Be antigen;
Entecavir;
Liuwei wuling pian
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;(14):2097-2098,2099
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the curative effect and safety of of Entecavir ( ETV) combined Liuweiwul-ing Pian in the treatment of chronic hepatitis B patients with HBeAg +.Methods 124 patients according to the ran-dom number table were divided into the two groups ,which respectively used ETV combined Liuweiwuling Pian treat-ment and ETV.The liver function and index of viral replication of the two groups were compared .Results The effec-tiveness of the observation group was 91.94%,which of the control group was 82.26%,the difference between the two groups had statistical significance(Ridit=32.251,P=0.000);Since 24 week treatment,HBV DNA of the observa-tion group was lower than the control group,the difference was statistically significant (t =2.365,4.595,all P<0.05);After treatment,ALT,AST of the observation group decreasing degree was higher than the control group ,the difference was statistically significant (t=78.512,62.145,all P<0.05);after treatment,the ALT rate,effective rate and bounce rate in the two groups was statistically significant differences (χ2 =25.621,46.241,11.512, all P<0.05);After treatment,the HBV DNA and HBeAg positive in two groups was below cut-off test cases,differences was statistically significant(χ2 =17.265,21.264,all P<0.05).Conclusion Entecavir combined Liuweiwuling Pian in the treatment of chronic hepatitis B patients with HBeAg +can reduce liver fibrosis , and has obvious detoxification and anti-viral.
